Answer
Caplacizumab, a humanised bivalent Nanobody, targets the A1-domain of von Willebrand factor, inhibiting its interaction with platelets and preventing ultra-large von Willebrand factor-mediated platelet adhesion.
Sources for this answer
- Cablivi 10 mg powder and solvent for solution for injectionSANOFI · emc · SmPC §5.1 Pharmacodynamic properties · Version 10Document updated
Sources checked